九典制药 reported revenue of ¥1.29B for the period ended 2026-06-30, -14.9% year on year. Net income was ¥0.16B, a 12.1% net margin on a 64.3% gross margin. The largest revenue line is 药品制剂 at 77% of the total. Free cash flow for the period was ¥0.12B.
| Item | Amount | Y/Y |
|---|---|---|
| Revenue | ¥1.29B | -14.9% |
| Gross profit | ¥0.83B | — |
| Operating income | ¥0.18B | — |
| Net income | ¥0.16B | -46.8% |
| Gross margin | 64.3% | Net margin 12.1% |
| Revenue Q/Q | +16.2% | — |
| Segment | Revenue | Share |
|---|---|---|
| 药品制剂 | ¥0.99B | 76.8% |
| 原料药 | ¥0.15B | 11.9% |
| 药用辅料 | ¥0.10B | 7.9% |
| 提取物及其他 | ¥0.04B | 2.7% |
| 技术转让及服务 | ¥0.01B | 0.6% |
| 其他(补充) | ¥0.00B | 0.1% |
| Item | Amount | % of revenue |
|---|---|---|
| Cost of revenue | ¥0.46B | 35.7% |
| R&D | ¥0.08B | 6.0% |
| SG&A | ¥0.55B | 43.0% |
| Tax & other | ¥0.03B | 2.0% |
| Item | Amount |
|---|---|
| Total assets | ¥4.18B |
| Total liabilities | ¥1.43B |
| Shareholders' equity | ¥2.75B |
| Equity / assets | 65.8% |
| Operating cash flow | ¥0.23B |
| Capital expenditure | ¥0.11B |
| Free cash flow | ¥0.12B |
| Cash conversion (OCF / net income) | 198% |
The Sankey chart shows how revenue splits into cost of revenue, R&D and SG&A, and what remains as profit — clean visuals for research decks and social posts.
阿石创 ・ 威唐工业 ・ 聚灿光电 ・ 精研科技 ・ 万隆光电 ・ 广哈通信 ・ 永福股份 ・ 英可瑞 ・ 凯伦股份 ・ *ST泉为 ・ 华信新材 ・ 长盛轴承
Source: Eastmoney · This page shows public filing data only, not investment advice. · Browse all companies